Venture Life Group (AIM:VLG), an AIM-listed consumer self-care company focused on products spanning women's health, ENT care and glucose management, reported revenues of £50 million for the seventeen months ended 31 May, a 30.9% increase on the equivalent prior period of £38.2 million.
On a pro forma basis, stripping out the impact of acquisitions, revenue grew 16%, of which 14.8 percentage points came from volume and 1.2 points from price increases, with adjusted EBITDA expected to land in line with market guidance.
The final five months of the period showed accelerating momentum, with group revenues up 28.9% to £14.7 million, led by the Power Brands, Balance Activ, Lift, Glucogel, Earol and Health & Her/Him, which grew 20.7% to £13.4 million and accounted for 91.2% of revenues in that window.
Net cash stood at approximately £12 million at 31 May, down from £34.2 million at 31 December 2025, with the movement largely reflecting a £17.5 million advance transfer for the FemiClear and CUROXEN acquisition completed on 2 June; adjusted free cash flow for the period was £5.9 million.
"FemiClear is the clear no.2 in the US Femcare market, delivering strong revenue growth in 2026 and into 2027," said chief executive Jerry Randall, describing the acquisition as a bridgehead for other VLG brands into the US.
Audited accounts for the seventeen-month period are scheduled for publication on 29 September.
